Crescendo Biologics shortlisted for *Private Financing Deal of the Year* at 2018 Scrip Awards

**Cambridge, UK, 1st October 2018** – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, has been shortlisted for *Private Financing Deal of the Year* at the 2018 Scrip Awards.

Now in its 14th year, the Scrip Awards recognises the innovation, dedication and hard work of both organisations and individuals over the past year in the pharmaceutical and biotech industries. The Scrip Awards prides itself on its Judging Panel, which is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

Crescendo has been nominated for its oversubscribed $70m Series B financing round, which it closed in April 2018. Crescendo added top tier investors from both Asia and Europe, with Andera Partners, (formerly Edmond de Rothschild), Quan Capital and Takeda Ventures joining an investor base which already included Sofinnova Partners and IP Group.

The financing round constituted the largest Series B in Europe at the time. The $70m raised will be used to progress Crescendo’s lead molecule, CB307, to clinical proof of concept, as well as funding its a follow-on pipeline of other tumour-targeted T-cell enhancers.

Details of the awards ceremony are as follows:

**Scrip Awards 2018**
Date: Wednesday 28 November 2018
Venue: The Hilton on Park Lane, Park Lane, London, W1K 1BE

For more information: [https://pharmaintelligence.informa.com/events/awards/scrip-awards-2018](https://pharmaintelligence.informa.com/events/awards/scrip-awards-2018)
For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO
+ 44 (0)1223 497140
info@crescendobiologics.com

For Media:
Instinctif Partners for Crescendo Biologics
Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com.